Mavacamten represents the first agent specifically developed for HCM successfully tested in a Phase III trial, to be registered soon for clinical use, representing a radical change of paradigm in the pharmacological treatment of HCM.
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy / Zampieri, M., Argirò, A., Marchi, A., Berteotti, M., Targetti, M., Fornaro, A., Tomberli, A., Stefàno, P., Marchionni, N., Olivotto, I.. - In: CURRENT CARDIOLOGY REPORTS. - ISSN 1523-3782. - ELETTRONICO. - 23:(2021), pp. 71-79. [10.1007/s11886-021-01508-0]
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy
Marchi, Alberto;Berteotti, Martina;Targetti, Mattia;Fornaro, Alessandra;Tomberli, Alessia;Stefàno, Pierluigi;Marchionni, Niccolò;Olivotto, Iacopo
2021
Abstract
Mavacamten represents the first agent specifically developed for HCM successfully tested in a Phase III trial, to be registered soon for clinical use, representing a radical change of paradigm in the pharmacological treatment of HCM.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Zampieri2021_Article_MavacamtenANovelTherapeuticStr.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
291.64 kB
Formato
Adobe PDF
|
291.64 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
